Sector News

Biodesix, Immodulon team up for pancreatic cancer treatment

July 31, 2019
Life sciences

Biodesix and Immodulon have announced a joint venture into biomarker research. The partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-101 using the Biodesix Diagnostic Cortex machine learning platform.

The Biodesix proprietary machine learning platform “builds on recent advances in the artificial intelligence field to uncover clinically relevant and elaborate biomarker patterns and relationships.” This In turn enables personalised approaches to therapy selection and a better understanding of complex diseases like cancer. IMM-101 is Immodulon’s investigational immunotherapeutic candidate under development for various tumour types, including advanced pancreatic cancer.

Dr Jaap Kampinga, Immodulon’s CEO, said that in the IMAGE I randomised clinical trial, metastatic pancreatic cancer patients receiving IMM-101 and gemcitabine benefitted from a “59% increase in median overall survival compared to those receiving gemcitabine alone.”

He continued, “There was considerable variability, as is typical in pancreatic cancer, with some patients surviving much longer than others. From this collaboration and by utilising the Biodesix Diagnostic Cortex in identifying blood-based proteomic biomarkers, we hope to facilitate selection of those patients most likely to respond to IMM-101. This could improve the efficiency of treatment and patient care, and accelerate our clinical trial programmes.”

Immodulon recently appointed Thomas O. Kleen as chief scientific officer of the Company.

By: Anna Smith

Source: Pharma Times

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend